13. The composition for use in a method of treatment or the method of treatment of claim 12, wherein the composition is encapsulated for oral administration.

14. The composition for use in a method of treatment or the method of treatment of any one of the preceding claims, wherein the amorphous magnesium-substituted calcium phosphate is capable of dispersing to form nanoparticles that are capable of uptake by CD11c positive cells and/or CD11c positive cells.

15. The composition for use in a method of treatment or the method of treatment of any one of the preceding claims, wherein amorphous magnesium-substituted calcium phosphate is capable of dispersing to form nanoparticles that are capable of uptake by dendritic cells and/or macrophages.

16. The composition for use in a method of treatment or the method of treatment of any one of the preceding claims, wherein the amorphous magnesium-substituted calcium phosphate is for use in a method of treating an autoimmune disease, cancer, food allergies and/or intolerances.

17. The composition for use in a method of treatment or the method of treatment of any one of the preceding claims, wherein the amorphous magnesium-substituted calcium phosphate is for use in a method of treating or preventing inflammatory bowel disease.

18. The composition for use in a method of treatment or the method of treatment of any one of the preceding claims, wherein the amorphous magnesium-substituted calcium phosphate is for use in a method of treating or preventing Crohn’s disease or coeliac disease.

19. The composition for use in a method of treatment or the method of treatment of any one of the preceding claims, wherein the amorphous magnesium-substituted calcium phosphate is for use